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Abstract 
Background  To evaluate the effect of intra-vitreal 
injection of Bevacizumab on Intra-ocular pressure  
Methods:  In this descriptive study sixty six 
patients who required intra-vitreal injection of 
Bevacizumab were enrolled. Patients with prior 
history of glaucoma, ocular hyper-tension, known 
allergy to Bevacizumab or who had prior injections of 
Bevacizumab were excluded from the study. Intra-
ocular pressure was measured in the eye, using a 
Goldmann applanation tonometer, prior to the 
injection and for the purpose of this study seven days 
after the injection. The pre- and post- injection Intra-
ocular pressure was entered into the database.  
Results: The mean age of the patient was 56.97 years 
(±13.805). The mean pre-injection intra-ocular 
pressure was 13.86 (±3.656) mmHg, while post-
injection mean IOP was 15.43 (±5.498) mmHg. There 
was a statistically significant rise in intra-ocular 
pressure after injection of Bevacizumab (p=0.01).   
Conclusion: Intra-vitreal injection of Bevacizumab 
is associated with a statistically significant rise in 
intra-ocular pressure.  
Key Words: Bevacizumab, Intra-ocular pressure, 
Intra-vitreal, Injection 
 
Introduction 
          The treatment of retinal vascular disorders 
associated with neo-vascularization has traditionally 
been managed with some form of laser treatment.1 Use 
of this form of treatment results in retinal tissue death 
which while reducing growth of neo-vascularization 
also diminishes visual function2. The treatment of other 
retinal disorders where photo-coagulation was 
employed to reduce vascular leakage like macular 
edema secondary to diabetes, vascular occlusion and 
vasculitis also produces some reduction in patient’s 
quality of vision3. Wet age related macular 
degeneration has also been managed with photo-
coagulative laser therapy4 as well as photodynamic 
therapy.4,5 Laser therapy was employed to control the 
spread of the disease6 while photodynamic therapy 
tended to stabilize the disease process often resulting 
in marginal improvement or stasis of visual function.6,7 
 Monoclonal antibody, Ranibizumab, targeting neo-
vascular membrane in wet age-related macular 
degeneration not only stabilizes the disease process but 
also regresses the neo-vascularization resulting in 
significant improvement in vision8. However the 
prohibitive cost of treatment of treatment has kept the 
wide spread acceptance of treatment not only in 
developing but developed world as well.9 A closely  
related drug to  Ranibizumab is Bevacizumab which is 
used for metastatic colo-rectal tumors.10 This drug has 
also been in the eye via an intra-vitreal route for 
controlling neo-vascularization of retinal or choroidal 
origin as well as reduced visual function secondary to 
macular edema.11,12 The clinical outcomes of both of 
these drugs have been reported to be similar.13 Recent 
reports reveal that use of either of these drugs can 
result in rise in intra-ocular pressure.14 
 
Patients and Methods 
   A total of 66 eyes of 66 patients were recruited from 
the out patients department of Shifa Foundation 
Community Health Center between January and 
December 2012. Inclusion criteria for recruitment was 
any applicable indication for injection of Bevacizumab, 
while the exclusion criteria included patients with 
prior history of glaucoma, ocular hyper-tension, 
known allergy to Bevacizumab or had prior injections 
of Bevacizumab. Patients with active ocular 
inflammation only eyed patients and patients with 
family history of glaucoma in first degree relatives 
were also excluded from the study.  
     Goldmann Applanation Tonometer was used to 
measure intra-ocular pressure (IOP) in all the patients 
by a single investigator who was blind to the study 
during morning hours to reduce the bias of time based 
variation of intra-ocular pressure15. After proper 
sterilization of the GAT head, the patient was seated 
comfortably in front of the slit lamp. The eye to be 
examined was anesthetized with topical 1% procaine 
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eye drops. The tear film was stained using a 
commercially available fluorescein strip. The patient 
was then asked to blink twice so as to uniformly 
spread the fluorescein dye. The pressure of the eye 
under examination was then measured. A total of three 
readings were taken and the average recorded.  
     The intra-vitreal injection of Bevacizumab was 
obtained in a prepared form (diluted to proper 
strength) for use in our patients. A dose of 
1.25mg/0.05ml of Bevacizumab was used in all our 
patients. Proparacaine (0.5%) topical eye drops were 
instilled in the eye as topical anesthesia. The eye and 
eyelids were disinfected with povidone solution. The 
drug was injected 4.0mm posterior to the corneal 
limbus in the vitreous cavity in a sterile environment 
ensuring asepsis. Sterile cotton tipped applicator was 
used after the injection to prevent reflux. All patients 
were prescribed Moxifloxacin eye drops QID for five 
days. All patients were asked to follow up 1 week after 
the injection for measurement of IOP in a manner 
similar to what has been described above.  
 
Results 
A total of 66 eyes of sixty six patients (40 males and 26 
females) were recruited for this study. The mean age of 
the patient was 56.97 years (±13.805),with a range of 3 
to 82 years. Most common indication being clinically 
significant macular edema associated with diabetes 
mellitus (n=53), while the least common indication was 
Neo-vascular glaucoma associated with vein 
obstruction (n=1) (Table 1).Reactive conjunctival 
hyperemia was by far the most common complication 
(Table 2). The pre-injection mean IOP was 13.86 
(±3.656), while post-injection mean IOP was 15.43 
(±5.498) mmHg. Paired t-test was used to analyze the 
pre- and post- injection IOP data. The level of 
significance was set at 5%; p <0.05 was taken to be 
significant.The pre- and post- injection IOP was found 
to be significantly different (p=0.01), with the post 
injection IOP being higher (Table 3).  
 
Table 1: Indications for intra-vitreal injection of 
Bevacizumab 
Indication No(%) 
Macular edema associated with diabetes 
mellitus  without proliferative changes 
53(80.3) 
Proliferative diabetic retinopathy 5(7.5) 
Wet Age Related Macular Degeneration  4 (6.0) 
Macular edema associated with venous 
obstruction 
3(4.5) 
Neo-vascular glaucoma secondary to venous 1(1.5) 
obstruction 
Table 2: Complication after intra-vitreal 
injection of Bevacizumab 
Complication No(%) 
Subconjunctival hemorrhage 23(34.8) 
Conjunctival chemosis 10(15.1) 
Drug reflux 2(3.0) 
 
Table 3: Mean pre- and post- injection Intra-
ocular pressure in patients 
 Pre-injection 
Intraocular 
pressure in 
mmHg 
Post-injection 
Intraocular pressure in 
mmHg 
Mean 13.86 15.43 
Std. 
Deviation 
3.656 5.498 
Minimum 7 7 
Maximum 23 33 
 
Discussion 
   Bevacizumab has been in use for several years for 
treatment of many retinal vascular disorders.16-19 Initial 
reports on their use did not always include the 
association of injection to a rise in intra-ocular 
pressure. We report a statistically significant (p=0.01) 
rise in intra-ocular pressure in our study population 
one week after an injection of Bevacizumab.   Adelman 
reported a persistent rise in intra-ocular pressure after 
injection of Bevacizumab in patients with no prior 
history of glaucoma or ocular hypertension.20 They 
reported that most of their cases developed a persistent 
rise after multiple injections. Our findings are in 
agreement with those of Adelman with the stipulation 
that in our patients the rise was seen after a single 
injection.  
    The delayed rate of intra-ocular elevation has also 
been investigated.21 Contrary to early rise in intra-
ocular pressure as shown in our study, this study 
shows that a delayed elevation of IOP does not occur 
after injections of Bevacizumab.  Factor behind the rise 
of IOP after injecting Bevacizumab have been looked 
into as well.22. Their study shows that patients 
receiving ≥29 injections were at a greater risk of 
developing a rise in IOP as compared to patients ≤12 
injections.  
    The rise in IOP has also been seen in patients who 
receive Ranibizumab instead of Bevacizumab for 
retinal vascular disorders23. This implies a common 
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end-point mechanism for rise in IOP after injection of 
either anti vascular endothelial growth factor drug.  
One explanation given for the rise in IOP is the 
variation in injection technique. It has been shown that 
a tunneled scleral injection is associated with a 
significantly greater rise in IOP24. Tunneled injections 
are employed to prevent reflux after injection25. All our 
patients received a straight scleral injection and we 
noticed a significant rise in IOP after the injection. 
Perhaps the rise in IOP would have been of a greater 
magnitude if we had employed a tunneled technique.  
     Another variable that has been shown to be 
responsible for rise in IOP is reflux at the injection site 
after the injection. It has been shown that patients with 
greater reflex have a lower tendency to develop a 
raised IOP as compared to patients in whom the reflux 
was smaller26. We did not observe nor categorized the 
reflux in our patients and as such cannot comment on 
how this related to patients in our study.  
    Although the volume of the vitreous does increase 
after the injection of Bevacizumab the rise in IOP 
caused by this alone is reported to transient dropping 
to near pre-injection levels with an hour after the 
injection27. We noticed a persistent rise in IOP at one 
week interval that cannot be explained alone on the 
basis of a rise in volume of the vitreous. The packaging 
and disbursement of the drug has also been implicated, 
but not proven to be causative in the rise of IOP28.  
    In all our patients the rise in IOP was controlled with 
topical administration of topical aqueous suppressants. 
They have been shown to be effective in controlling 
rise in IOP after intra-vitreal injections28. In rare cases 
trabeculectomy surgery has also been carried out to 
control a persistent rise in IOP29. None of our patients 
required surgery for return to normal levels of IOP. 
Combination of an alpha-agonist and beta-blocker has 
been shown to be effective in prophylaxis of IOP rise 
associated with injections of Bevacizumab30.   
     Bevacizumab was initially employed for use in wet 
ARMD, it now sees wide spread use in many retinal 
and even anterior segment ocular pathologies31. Our 
indications were limited to posterior segment 
pathologies which correlate well with those of other 
locally published results32. 
      In present study conjunctival hyperemia was a 
common complication, though it was transient and 
resolved on its own without sequlae. No treatment was 
required for other complications as well; all of them 
settled on their own. In our study we did not 
experience posterior segment complications which 
have been reported in literature.33 Patient factors, 
sample size, indications for injection are predictors for 
complications seen in patients. A regional study by 
Fasih et al also noticed a majority of anterior segment 
complications and vitreous hemorrhage in one patient 
(n=150). 32  
Conclusion 
There is a statistically significant rise in IOP after an 
intra-vitreal injection of Bevacizumab. Clinicians 
should be alert to this complication and in light of the 
findings of and quoted in our study offer a prophylaxis 
to their patients or aggressively manage the IOP if the 
rise is persistent.  
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